A RANDOMIZED, DOUBLE BLIND, MULTIPLE DOSING (14 DAYS), PLACEBO-CONTROLLED, INCOMPLETE BLOCK CROSSOVER, MULTI CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF THREE DOSE LEVELS OF AZD7594, GIVEN ONCE DAILY BY INHALATION, IN PATIENTS WITH MILD TO MODERATE ASTHMA
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs AZD 7594 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 16 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Nov 2015 Planned End Date changed from 1 May 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.